By Esther Bachar-Lustig, Assaf Lask, Yaki Eidelstein, Noga Or-Geva, Rotem Gidron-Budovsky, Bar Nathansohn-Levy, Matthias Eyrich, Wei-Hsin Liu, Giang Dang, Karla Castro Miranda, Alejandro Ramirez, Indreshpal Kaur, Katayoun Rezvani, Elizabeth Shpall, Richard E Champlin, Arnon Nagler, Avichai Shimoni, Sivan Barnees-Kagan, Yair Reisner
BACKGROUND: Previous studies in mice demonstrated that CD8 T-cells exhibit marked veto activity enhancing engraftment in several models for T cell depleted bone marrow (BM) allografting. To reduce the risk of graft versus host disease (GVHD) associated with allogeneic CD8-veto T-cells, these studies made use of naive CD8 T-cells stimulated against third-party stimulators under cytokine deprivation and subsequent expansion in the presence of IL15. More recently it was shown that mouse CD8 veto T-cells can be generated by stimulating CD8 memory T-cells from ovalbumin immunized mice under cytokine deprivation, using ovalbumin as a third-party antigen...
October 25, 2023: Transplantation and cellular therapy